Medspray has joined forces with contract development and manufacturing organization Recipharm in the joint venture Resyca BV. Together, they will develop and exploit a unique soft mist spray nozzle technology for pharmaceutical applications.
The soft mist spray nozzle technology has the potential to eliminate the need for propellants. Because it delivers therapies deep into the lungs instead of it ending up in a patient’s mouth or throat, treatments become more effective while using lower doses.
Han van Egmond, CEO of Medspray: “Our partnership with Recipharm underlines the exciting opportunities we see for the soft mist spray nozzle technology in pharmaceutical applications. The potential advantages to both patients and environment make a highly compelling case for its adoption”.
Jean-François Hilaire, EVP Strategy and Global Integration, Recipharm AB adds: “The fit with Recipharm broader inhalation activities is very clear and is part of our strategy to be the world leading integrated device development and manufacturing provider”.
Recipharm’s investment in Resyca has been made through its subsidiary Recipharm BV. Resyca will operate development facilities in Munich, Germany and Medspray will be the exclusive supplier for spray nozzles. Commercial supply of finished devices is expected to be manufactured and supplied by other Recipharm affiliates, including the specialist device manufacturing capabilities in King’s Lynn, UK.
Recipharm will also receive an exclusive license to offer its customers the development and manufacturing of syringe-based devices using the soft mist nozzle technology. Such devices will be marketed by Recipharm under the brand Bespak by Recipharm.
About the soft mist technology
Using lithography and etching techniques from the semiconductor world, tiny pores can be created in ultrathin membranes. The pore size, which can be designed accurately between 1.5 and 15 microns, determines the droplet size by laws of physics. If a simple hydraulic pressure is applied, liquid jets emerge from the pores, like a micron sized garden sprayer.
No electricity, a simple and robust mechanical system is all it takes. By mixing the droplets with the inhalation air stream, a slow-moving cloud of soft mist is generated. The selected existing fill and finish platform of prefilled glass syringes, with the soft mist nozzles already mounted, gives good stability of the drug formulation over the shelf life, even for the complex biologic drugs of the near future.
For more information on Recipharm, please visit www.recipharm.com
Want to stay updated on the developments in this joint venture? Stay in touch through our social channels!
